X
GO

Dr. Michele Carbone's Scientific Publications

Mesothelioma: Recent Highlights

Mesothelioma: Recent Highlights

Annals of Translational Medicine 2017: Review Article

Recent discoveries have elucidated some of the mechanisms responsible for the development of mesothelioma. 
0 Comments
FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model

FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model

Journal of Translational Medicine

Abstract Malignant mesothelioma (MM) is a very aggressive type of cancer, with a dismal prognosis and inherent resistance to chemotherapeutics. Development and evaluation of new therapeutic approaches is highly needed. Immunosuppressant FTY720, approved for multiple sclerosis treatment, has recently raised attention for its anti-tumor activity in a variety of cancers. However, its therapeutic potential in MM has not been evaluated yet.
0 Comments
Oncotarget Advance Publication: HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma

Oncotarget Advance Publication: HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma

We studied the effect of ethyl pyruvate (EP), the ethyl ester of pyruvic acid, on the malignant phenotype of MM cells in tissue culture and on tumor growth in vivo using an orthotopic MM xenograft model.
0 Comments
Aspirin may delay growth of asbestos-related cancer

Aspirin may delay growth of asbestos-related cancer

Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression

Aspirin (acetylsalicylic acid, ASA) is the most widely used nonsteriodial anti-inflammatory drug that reduces the incidence, metastatic potential and mortality of many inflammation-induced cancers.  Can it play a role in helping patients with malignant mesothelioma?
0 Comments
RSS